Skip to content

News   /   Uncategorized

Insights (Another Biotech Unicorn)

Insights (Another Biotech Unicorn)
August 21, 2023

Another biotech unicorn is made… 

Biotech company Mammoth Biosciences just hit unicorn status after getting $195 million in funding this year. Mammoth Biosciences uses CRISPR technology for molecular diagnostics. In other words, it uses CRISPR to test for genetic diseases. Notably, it was co-founded by Jennifer Doudna, who was one of the original inventors of CRISPR technology back in 2012.  

The company has done a lot of research on genetic engineering but hasn’t quite picked out the direction it wants to go yet. What we do know is it aims to create treatments for tissues that are hard to target, such as the central nervous system or lungs. And Mammoth Bio has already inked deals with Agilent and GlaxoSmithKline

It’s a name to watch in the space.  What makes Mammoth so compelling is that it develops very small enzymes – Cas-14 and Casɸ. These small gene editing treatments are better able to fit into delivery vehicles and pack more features in the treatment. This is important since Mammoth plans to create in vivo therapeutic approaches

For in vivo therapies, we inject the treatment directly into a body part or organ. It is simpler and cheaper to administer the CRISPR technology in this way. It is also believed to lead to higher levels of efficacy in delivering the payload and addressing the disease. It contrasts ex vivo therapies, in which cells are extracted, edited, and reinserted.

Share this article:

More in Uncategorized:

Best of US Investors

A Safe Way to Invest in Cannabis with Innovative Industrial Properties

The U.S. cannabis industry remains highly fragmented and risky, but there is one outlier that provides investors with a relatively...

Trent Grinkmeyer in front of stock market with bull background

Trent Grinkmeyer
May 17, 2024

Best of US Investors

7 Stocks With Cosmic Potential - Finding the Next "Moonshot" Investments

May 16, 2024 By Kerry Grinkmeyer There are only two main ways to make big money in the stock market....

Insights (Another Biotech Unicorn)
May 16, 2024

Best of US Investors

Unveiling the Future with Emily Leproust and Twist Biosciences

In a world grappling with environmental challenges and the relentless pursuit of longevity, a visionary figure has emerged – Emily...

Kerry Grinkmeyer in a suit standing in front of a stock chart with a bull on it

Kerry Grinkmeyer
May 15, 2024

Best of US Investors

Uncovering Explosive Growth Potential: The Case for Navitas Semiconductor (NVTS)

As investors, we’re constantly on the hunt for opportunities that offer substantial upside potential. In the ever-evolving world of semiconductors,...

Kerry Grinkmeyer in a suit standing in front of a stock chart with a bull on it

Kerry Grinkmeyer
May 15, 2024

Best of US Investors

Are We Headed for Stagflation? Examining the Economic Warning Signs

The latest economic data continues to show stubbornly high inflation, with the Producer Price Index (PPI) up again in April...

Trent Grinkmeyer in front of stock market with bull background

Trent Grinkmeyer
May 14, 2024

Best of US Investors

Job Growth Slows but Remains Solid in April

The U.S. labor market remained resilient in April, though job growth decelerated slightly amid cooling wage pressures, according to the...

Insights (Another Biotech Unicorn)
May 1, 2024

Register for the Best of US Investors Newsletter

Get daily financial news delivered to your inbox. Join today.

©2024 Best of US Investors. All rights reserved.

Site by KMA

Disclaimer

This Best of US Investors website is not and should not be considered investment advice. This Best of US Investors website is for informational purposes only. Nothing on this Best of US Investors website constitutes a recommendation to buy, sell or hold any security at any time. Always consult with a financial professional that is familiar with your specific situation before making any investment or trade.

Use of this Best of US Investors website is at your own risk. Best of US Investors makes no warranties about the accuracy, completeness or reliability of any content on this Best of US Investors website.

All the information on this Best of US Investors website is provided “AS IS”. Do not rely on any statements made on this Best of US Investors website.

In no event shall Best of US Investors be responsible or liable for any damage that occurs while using or reading any content on this Best of US Investors website.

Best of US Investors may have a position (long, short or neutral) in any security mentioned on this Best of US Investors website and therefore may realize significant gains in the event that the price of the security mentioned on this Best of US Investors website declines or appreciates.

Best of US Investors may buy and/or sell any security mentioned on this Twitter account at any time and for any reason. I may trade contrary or different to the information provided on this Best of US Investors website. You should assume that any email or post on this Best of US Investors website may cause the price of the security mentioned to appreciate or decline in a dramatic way.

Best of US Investors may continue to transact in any security mentioned on this Best of US Investors website an indefinite period of time after any email or post and such positions may be long, short or neutral at any time hereafter regardless of the initial view or positions stated on this Best of US Investors website.

In no event shall Best of US Investors be liable for any claims, losses, costs or damages of any kind including direct, indirect, punitive, exemplary, incidental, special or consequential damages, arising out of or in any way connected with any information presented on this Best of US Investors website. This limitation of liability applies regardless of any negligence or gross negligence of Best of US Investors or any company affiliated with Best of US Investors. You accept all risks in relying on the information presented on this Best of US Investors website.

If any statement in this legal disclaimer is held to be invalid or unenforceable, then the remaining provisions shall continue in full force and effect.

For more information, contact [email protected] .